NCT06277635View on ClinicalTrials.gov

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases

NARecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Rheumatoid ArthritisPsoriatic ArthritisPsoriasis
Interventions
DRUG

Silymarin

Silymarin is randomly assigned to the participants for 12 weeks during study.

DRUG

Placebo

Placebo is randomly assigned to the participants for 12 weeks during study.

Trial Locations (1)

10400

RECRUITING

Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, 10400

All Listed Sponsors
lead

Phramongkutklao College of Medicine and Hospital

OTHER

NCT06277635 - Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases | Biotech Hunter | Biotech Hunter